Joel Greenblatt’s Aurinia Pharmaceuticals AUPH Stock Holding History

Joel Greenblatt’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18M	Sell	128,322 -40,276	-24%	-$643K	0.01%	1119
2026 Q1	$2.5M	Buy	168,598 +41,211	+32%	+$602K	0.01%	1045
2025 Q4	$2.03M	Buy	127,387 +46,634	+58%	+$661K	0.01%	1034
2025 Q3	$892K	Sell	80,753 -7,738	-9%	-$84.5K	﹤0.01%	1239
2025 Q2	$750K	Buy	88,491 +5,455	+7%	+$43.7K	﹤0.01%	1217
2025 Q1	$668K	Buy	83,036 +38,040	+85%	+$308K	0.01%	1132
2024 Q4	$404K	Buy	44,996 +3,655	+9%	+$29.8K	﹤0.01%	1191
2024 Q3	$303K	Buy	41,341 +1,049	+3%	+$6.5K	﹤0.01%	1218
2024 Q2	$230K	Buy	+40,292	New	+$212K	﹤0.01%	1298
2023 Q3	–	Sell	-39,733	Closed	-$385K	–	1325
2023 Q2	$385K	Sell	39,733 -55,147	-58%	-$572K	0.01%	1050
2023 Q1	$1.04M	Buy	+94,880	New	+$836K	0.03%	731

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Joel Greenblatt's AUPH Position: Q2 2026 in Review

Joel Greenblatt reduced its Aurinia Pharmaceuticals (AUPH) stake by 24% in Q2 2026, selling an estimated $643K and leaving 128,322 shares worth $2.18M. The position accounts for 0.01% of the portfolio, ranked #1119.

Joel Greenblatt first reported a position in AUPH in Q1 2023 and has held it in 11 quarters since. The position peaked at $2.5M in Q1 2026. 279 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Joel Greenblatt held 128,322 shares of Aurinia Pharmaceuticals worth $2.18M as of Q2 2026.
Joel Greenblatt sold 40,276 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $643K.
Aurinia Pharmaceuticals made up 0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1119 holding.
Joel Greenblatt first reported a position in Aurinia Pharmaceuticals in Q1 2023 and has held it in 11 quarters since.
Joel Greenblatt's Aurinia Pharmaceuticals position peaked at $2.5M in Q1 2026.
279 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.